Assembly Biosciences announced interim results from its Phase 1b clinical study of ABI-4334 for chronic hepatitis B, as detailed in a press release dated December 26, 2024.
AI Assistant
ASSEMBLY BIOSCIENCES INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.